In early 2023, our team made a series of predictions about the oncology market and how it would likely develop during the year. This paper, written in early 2024, looks back at those predictions and assesses their accuracy. The team addresses topics such as cancer vaccines, radiopharmaceuticals, bi-specifics, CAR-T therapies, antibody drug conjugates, and minimal residual disease (MRD) measurement.
